Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433034 | 0.84 | MGLL (0.38) | SPRMGLLHCRTR1HSD11B1TRPV4 | |
| SCHEMBL17110212 | 0.74 | ALDH1A1 (0.36) | HSD11B1MAPTKMT2AHSD17B10NOTUM | |
| SCHEMBL17110437 | 0.74 | TRPV4 (0.38) | MGLLTRPV4 | |
| SCHEMBL17097546 | 0.73 | ALDH1A1 (0.37) | SPRHSD11B1MAPTKMT2A | |
| SCHEMBL21816121 | 0.70 | NOTUM (0.49) | SPRMAPK1MGLLHSD11B1TRPV4 | |
| SCHEMBL17117977 | 0.70 | TRPC1 (0.40) | SPRRAB9AMEN1MAPTTSHR | |
| SCHEMBL16654536 | 0.67 | SPR (0.38) | SPRHSD11B1TRPV4 | |
| SCHEMBL17110424 | 0.67 | PRMT1 (0.37) | TRPV4MAPTKMT2AHSD17B10 | |
| SCHEMBL17049011 | 0.66 | KDM4E (0.33) | SPRHSD11B1MAPT | |
| SCHEMBL574429 | 0.65 | TRPV4 (0.43) | SPRMGLLHSD11B1TRPV4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | SPR 2752/4885MAPK1 2696/4885MGLL 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.